header
March 12, 2021

In This Issue
The Year a Global Pandemic Changed Our Lives; Thank You Maine Physicians
APRN Training & Supervision: “Laws are Like Sausages. Better Not to See Them Being Made”
Governor Amends Vaccination Timeline; All Adults Eligible for COVID-19 Vaccine by May 1
Covid-19: Both Vaccinations Now Done and Done: Richard A. Evans MD
Maine DHHS: Strategies for Addressing Disparate Impacts of COVID-19
US FDA: Coronavirus (COVID-19) Update: March 12, 2021
Abyde joins with Maine Medical Association as a new Corporate Affiliate
Next MMA Legislative Call Will Be Wednesday, March 17th
Daniel Hanley Center for Health Leadership’s Renowned Physician Executive Leadership Institute – The Advanced Course Enrollment is OPEN
PPE Available Through the MMA & ActionPPE
A Message from Maine Responds: Volunteer Opportunity
MAINE LEGISLATURE
Maine Legislature Week 9 Update
Maine Legislature: Public Hearings, Work Sessions, New Bills
UPCOMING EVENTS
Upcoming Specialty Society Meetings
Maine Lung Cancer Coalition Webinar March 24, 2021
Maine CDC Physicians To Host Regular Clinician COVID Vaccine Info Sessions
Suicide Prevention and Management in Healthcare Practice Settings: A Comprehensive Evidence-Based Approach
AAP EQIPP Course: Immunizations - Strategies for Success (for RURAL Health Providers)
HEALTHCARE EMPLOYMENT OPPORTUNITIES
Nurse Practitioner
Physician
Psychiatric Nurse Practitioner
Belgrade Regional Health Center Seeks a Physician (BC/BE in Family Medicine)

 
Search Back Issues



 

 

 


Follow Us:
US FDA: Coronavirus (COVID-19) Update: March 12, 2021

The U.S. Food and Drug Administration (FDA) continued to act in the ongoing response to the COVID-19 pandemic: 

As part of the FDA’s effort to protect consumers, the agency issued a warning letter to Cannafyl for selling unapproved products with fraudulent COVID-19 claims. The company sells CBD-containing products, including “Balance CBD Drops,” “Relief CBD Drops,” “Relax CBD Drops” and “Relief CBD Salve,” and misleadingly represents the products can mitigate, prevent, treat, diagnose or cure COVID-19 in people. The FDA requested that Cannafyl take immediate action to cease the sale of any unapproved and unauthorized products for the treatment or prevention of COVID-19. Consumers concerned about COVID-19 should consult with their health care provider. 

Today, the FDA issued a Letter to Clinical Laboratory Staff, Point-of-Care Facility Staff and Health Care Providers to alert them that false positive results can occur with the Roche Molecular Systems, Inc. cobas SARS-CoV-2 & Influenza A/B Nucleic Acid Test for use on the cobas Liat System. 

Today, the FDA issued an Emergency Use Authorization (EUA) for Propofol-Lipuro 1% injectable emulsion for infusion to maintain sedation via continuous infusion in patients greater than 16 years old who require mechanical ventilation in an intensive care unit setting during the COVID-19 public health emergency. Propofol-Lipuro 1% injectable emulsion for infusion is not FDA-approved and has important differences in its formulation compared to FDA-approved propofol drugs; providers should consult the Health Care Provider Fact Sheet for more information before administering it. 

Testing updates: 

As of today, 341 tests and sample collection devices are authorized by the FDA under EUAs. These include 254 molecular tests and sample collection devices, 72 antibody and other immune response tests and 15 antigen tests. There are 38 molecular authorizations that can be used with home-collected samples. There is one molecular prescription at-home test, two antigen prescription at-home test, one OTC at-home antigen test and one OTC molecular test. 

More FDA COVID-19 updates can be found here.

< Previous Article | Next Article >

[ return to top ]

To ensure delivery of Maine Medicine Weekly Update,
please add 'info@mainemed.com' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details: http://www.commpartners.com/website/white-listing.htm


Unsubscribe here

For more information or to contact us directly, please visit www.mainemed.com | ©